Kim Ma - Odonate Therapeutics VP Operations
| ODTCDelisted Stock | USD 1.80 0.00 0.00% |
Insider
Kim Ma is VP Operations of Odonate Therapeutics
| Phone | 332 206 0935 |
| Web | https://www.odonate.com |
Odonate Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3309) % which means that it has lost $0.3309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8614) %, meaning that it created substantial loss on money invested by shareholders. Odonate Therapeutics' management efficiency ratios could be used to measure how well Odonate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Odonate Therapeutics currently holds 4.85 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Odonate Therapeutics has a current ratio of 3.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Odonate Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Odonate Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Odonate Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Odonate to invest in growth at high rates of return. When we think about Odonate Therapeutics' use of debt, we should always consider it together with cash and equity.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. The company was founded in 2013 and is based in New York, New York. Odonate Therapeutics operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 137 people. Odonate Therapeutics [ODTC] is a Pink Sheet which is traded between brokers as part of OTC trading. Odonate Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. Management Performance
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.33 |
Odonate Therapeutics Leadership Team
Elected by the shareholders, the Odonate Therapeutics' board of directors comprises two types of representatives: Odonate Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Odonate. The board's role is to monitor Odonate Therapeutics' management team and ensure that shareholders' interests are well served. Odonate Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Odonate Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tracey McKennon, VP Assurance | ||
| Kim Ma, VP Operations | ||
| Steven Pfeiffer, VP Operations | ||
| Thomas Wei, Chief Officer | ||
| Stewart Kroll, Chief Officer | ||
| Kevin Tang, Chairman CEO | ||
| Jennifer Schroeder, VP Technology | ||
| Michael Hearne, CFO Officer | ||
| Ryan Cole, VP Operations |
Odonate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Odonate Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (26.67 M) | ||||
| Shares Outstanding | 38.49 M | ||||
| Shares Owned By Insiders | 3.61 % | ||||
| Shares Owned By Institutions | 9.60 % | ||||
| Number Of Shares Shorted | 379.63 K | ||||
| Price To Book | 0.89 X | ||||
| EBITDA | (125.91 M) | ||||
| Net Income | (126.35 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in Odonate Pink Sheet
If you are still planning to invest in Odonate Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Odonate Therapeutics' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |